Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 794 participants.
Also called NCT02887183
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 794 participants
- Sponsor
- Registry
-
NCT02887183
-
- Other papers using this trial's data
- Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study
- Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
- Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study
- Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02887183. Allocation not applicable; no masking; primary purpose other. Start 2016-10-25 (actual); primary completion 2018-10-22 (actual). Results posted on 2019-12-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
- Acronym
- PROVE-HF
- Condition
- Heart Failure
- Intervention (Drug)
- LCZ696 (sacubitril/valsartan)
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02887183- Content hash
866af7c8ecde0a3e2474582ea59e6c3795eb6f2be957b7542535f3c51aab83f8